Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. (Q34662482)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Federico Cappuzzo

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Edward B Garon

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Tudor-Eliade Ciuleanu

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Kumar Prabhash

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Konstantinos N Syrigos

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Tuncay Goksel

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Keunchil Park

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Vera Gorbunova

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ruben Dario Kowalyszyn

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Joanna Pikiel

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Grzegorz Czyzewicz

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Conrad R Lewanski

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Michael Thomas

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Paolo Bidoli

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Shaker Dakhil

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Steven Gans

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Joo-Hang Kim

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Alexandru Grigorescu

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Nina Karaseva

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Martin Reck

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Ekaterine Alexandris

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Andreas Sashegyi

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sergey Yurasov

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Maurice Pérol

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

0 references

publication date

2 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

384

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

9944

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

665-673

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24933332%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Current treatments for advanced stage non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment ration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival: meaningful or simply measurable?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960845-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34662482&oldid=1577693137"